ADIL On July 17, 2020, Adial Pharmaceuticals, Inc., a Delaware corporation (the “Company”), received notice that the European Medicines Agency (EMA) has accepted the Pediatric Investigation Plan (PIP) submitted by the Company for development of the Company’s lead drug candidate, AD04, for the treatment of alcohol use disorder in the pediatric population, ages 12 to 17. As part of the regulatory process for the registration of new medicines in Europe, pharmaceutical companies are required to provide a PIP outlining their strategy for investigation of the new medicinal product in the pediatric population. An approved PIP is a prerequisite for filing a Marketing Authorization Application (MAA) for a new medicinal product in the European Union.
News 
Market Data 
Discover 
